

COT Evaluation Timeline

In this guide

[In this guide](#)

1. [Annex A TOX/2025/47 - Introduction](#)
2. [Annex A TOX/2025/47 - Evaluations prior to the 2023 EFSA Opinion](#)
3. [Annex A TOX/2025/47 - Evaluations by Regulatory bodies since the EFSA 2023 Opinion](#)
4. [Annex A TOX/2025/47 - COT review of BPA](#)
5. [Annex A TOX/2025/47 - Overall conclusion by the COT](#)
6. [Annex A TOX/2025/47 - COT Evaluation Timeline](#)
7. [Annex A TOX/2025/47 - Abbreviations](#)
8. [TOX/2025/47 Annex A - References](#)
9. [TOX/2025/47 Annex A - Literature search on the reproductive toxicity, immunotoxicity, pathology and histopathology of BPA](#)

This is a background paper for discussion. It has not been finalised and should not be cited.

Discussion of the Draft EFSA Opinion (2022; [TOX/22/11-16](#)).

Discussion of the EFSA 2023 Opinion ([TOX/23/25](#)); COT First draft interim position statement.

TOX/23/45: [Second draft interim position statement on bisphenol A](#).

TOX/23/50: [Third draft interim position statement on bisphenol A](#).

TOX/23/61: [Bisphenol A: The Dutch National Institute for Public Health and the Environment \(RIVM\), BPA Part 2](#).

TOX/24/08: [Fourth draft interim position paper on bisphenol A](#).

TOX/24/13: [Fifth Draft Interim Position Statement on Bisphenol A](#).

TOX/24/19: [Sixth draft interim position statement on bisphenol A](#).

[COT Position Paper on Bisphenol A \(BPA\)](#).

COT supplementary statement

December 2025